Norepinephrine-Dopamine Reuptake Inhibitors (NDRIs)
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting, stopping, or changing any medication. Using this site does not create a doctor-patient relationship.
Drug information changes as the FDA updates labeling, and we cannot guarantee it is complete or current. Verify critical details with your pharmacist or physician.
Emergencies: If you think you may have a medical emergency, call 911 immediately. For a suspected overdose, call Poison Control at 1-800-222-1222. Report side effects to the FDA MedWatch program at fda.gov/medwatch or 1-800-FDA-1088.
See our Terms of Use and Editorial Policy.
Overview
NDRIs are antidepressants that enhance the activity of norepinephrine and dopamine by blocking their reuptake into presynaptic neurons. Bupropion is the primary agent in this class, used for major depressive disorder, seasonal affective disorder, and smoking cessation.
How do norepinephrine-dopamine reuptake inhibitors (ndris) work?
NDRIs competitively inhibit the neuronal reuptake transporters for norepinephrine (NET) and dopamine (DAT), increasing synaptic concentrations of both neurotransmitters. Unlike SSRIs and SNRIs, they have minimal effect on serotonin reuptake and no significant activity at postsynaptic receptors.
Drugs in this class
- Bupropion (Wellbutrin, Wellbutrin XL, Zyban)